Product Images Teriflunomide

This is a graph showing Disability Progression Sustained for 12 weeks in patients who took either a placebo, 7 mg teriflunomide tablets, 14 mg teriflunomide tablets or 40 mg teriflunomide tablets. The y-axis is the number of patients while the x-axis is the number of weeks. The graph shows that the teriflunomide (7mg, 14mg, and 40mg) tablets have a significant effect on reducing disability progression compared to the placebo.*

This is a table of results obtained after 12 weeks of treatment with different doses of teriflunomide, a medication used to treat multiple sclerosis. The table shows the percentage of patients who experienced relapses during the treatment, as well as the number of patients at risk for each treatment. There are different doses of teriflunomide tablets (7mg and 14mg), and a placebo. It is not possible to provide a useful description without further context, as the table only contains numerical values and lacks information on the design, methodology, and purpose of the study.*

Teriflunomide Tablets are used orally once daily to treat multiple sclerosis. Each tablet contains 14 mg of teriflunomide, and it can be taken with or without food. The tablets should be stored at controlled room temperature and kept away from children. A medication guide is enclosed with the tablets and should be provided to each patient. NDC 0115 1565 44 is the product's identification number.*